EP2536688A4 - Stabile dosierungsformen von levomilnacipran - Google Patents

Stabile dosierungsformen von levomilnacipran

Info

Publication number
EP2536688A4
EP2536688A4 EP11733447.4A EP11733447A EP2536688A4 EP 2536688 A4 EP2536688 A4 EP 2536688A4 EP 11733447 A EP11733447 A EP 11733447A EP 2536688 A4 EP2536688 A4 EP 2536688A4
Authority
EP
European Patent Office
Prior art keywords
levomilnacipran
dosage forms
stable dosage
stable
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11733447.4A
Other languages
English (en)
French (fr)
Other versions
EP2536688A1 (de
Inventor
Rahul Surana
Murali Divi
Anil Chhettry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/941,293 external-priority patent/US8865937B2/en
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of EP2536688A1 publication Critical patent/EP2536688A1/de
Publication of EP2536688A4 publication Critical patent/EP2536688A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP11733447.4A 2010-01-14 2011-01-14 Stabile dosierungsformen von levomilnacipran Withdrawn EP2536688A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29489810P 2010-01-14 2010-01-14
US12/941,293 US8865937B2 (en) 2009-11-06 2010-11-08 Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
PCT/US2011/021315 WO2011088331A1 (en) 2010-01-14 2011-01-14 Stable dosage forms of levomilnacipran

Publications (2)

Publication Number Publication Date
EP2536688A1 EP2536688A1 (de) 2012-12-26
EP2536688A4 true EP2536688A4 (de) 2014-04-02

Family

ID=44304671

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11733447.4A Withdrawn EP2536688A4 (de) 2010-01-14 2011-01-14 Stabile dosierungsformen von levomilnacipran

Country Status (4)

Country Link
EP (1) EP2536688A4 (de)
JP (1) JP2013517290A (de)
CA (1) CA2790933A1 (de)
WO (1) WO2011088331A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2978350B1 (fr) * 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
CN110711185A (zh) * 2018-07-11 2020-01-21 北京万全德众医药生物技术有限公司 左旋米那普仑缓释胶囊

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008495A1 (fr) * 1996-08-28 1998-03-05 Pierre Fabre Medicament Forme galenique a liberation prolongee de milnacipran
US20040162334A1 (en) * 2003-02-14 2004-08-19 Jean Deregnaucourt Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
WO2009127737A1 (en) * 2008-04-18 2009-10-22 Pierre Fabre Medicament Use of enantiomer (1s, 2r) of milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients
WO2010129689A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Milnacipran formulations
WO2011057176A1 (en) * 2009-11-06 2011-05-12 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034101A1 (en) * 2001-11-05 2004-02-19 Cypress Bioscience, Inc. Treatment and prevention of depression secondary to pain (DSP)
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1908461B9 (de) * 2003-02-14 2011-08-31 Pierre Fabre Medicament Verwendung des Enantiomers (1S, 2R) von Milnacipran zur Herstellung eines Arzneimittels
JP5036029B2 (ja) * 2005-06-10 2012-09-26 旭化成ファーマ株式会社 安定化されたミルナシプラン製剤
JP2008273867A (ja) * 2007-04-27 2008-11-13 Asahi Kasei Pharma Kk 経粘膜投与用製剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008495A1 (fr) * 1996-08-28 1998-03-05 Pierre Fabre Medicament Forme galenique a liberation prolongee de milnacipran
US20040162334A1 (en) * 2003-02-14 2004-08-19 Jean Deregnaucourt Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug
WO2009127737A1 (en) * 2008-04-18 2009-10-22 Pierre Fabre Medicament Use of enantiomer (1s, 2r) of milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients
WO2010129689A1 (en) * 2009-05-05 2010-11-11 Forest Laboratories Holdings Limited Milnacipran formulations
WO2011057176A1 (en) * 2009-11-06 2011-05-12 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011088331A1 *

Also Published As

Publication number Publication date
JP2013517290A (ja) 2013-05-16
CA2790933A1 (en) 2011-07-21
WO2011088331A1 (en) 2011-07-21
EP2536688A1 (de) 2012-12-26

Similar Documents

Publication Publication Date Title
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
ZA201304158B (en) Dosage form
HRP20211969T1 (hr) Farmaceutski pripravak karbetocina
TWM389827U (en) Improved structure of lamp
PL2407155T3 (pl) Formulacje inekalcytolu
EP2684869A4 (de) Herstellung von 3-mercaptopropionaten
EP2536693A4 (de) Substituierte 2-imidazolidone und analoga
EP2536688A4 (de) Stabile dosierungsformen von levomilnacipran
GB201001203D0 (en) Use of pharmaceutically active compounds
ZA201304079B (en) Dosages of arylsulfonamide derivatives
HK1160777A1 (en) Novel use of neohesperidoside
TWM390860U (en) Structure of granulator
GB201018917D0 (en) Dosage form
GB201011271D0 (en) Dosage Form
HU1000688D0 (en) Use of trifluoro-phal
TWM390349U (en) Structure of door-in-door
TWM386865U (en) Residue-filtering structure of juice-extractor
TWM400763U (en) Improved structure of cold-accumulating cravats
TWM388315U (en) Improved structure of hemoclip
TWM390745U (en) Structure improvement of tea-making can
GB201104632D0 (en) Use of medicament
GB201009614D0 (en) Therapeutic use of compounds
TWM390794U (en) Improved structure of mask
TWM401163U (en) Improved structure of mouse
TWM385287U (en) Tilting-angle-adjusting structure of chair

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120718

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140303

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/48 20060101AFI20140225BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141001